Renal care company gets $20 million for development
This article was originally published in Clinica
In-Line Diagnostics, a small privately-funded renal care company that is developing non-invasive technology to measure whole blood constituents during dialysis, has raised private equity funding of $20 million. The money will be used to take the technology into new areas.
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.